With an educational background in Pharmacy Bob Kool started his career as pharmacy practitioner in his own pharmacy in Roermond. During this period he was active in the board of the Dutch pharmacist branch organisation (KNMP), section Limburg.
Kool was also member of the board of Regifarm, a pharmaceutical wholesale cooperation in Rotterdam, where he was involved in the establishment of a generics division. Together with Jacques Havermans he founded a generics company for the Regifarm Group. Kool worked as a consultant for Arcadis BMB SENTER projects as a pharmaceutical expert in designing and building a factory for the production of generics in Russia and Bulgaria. In 2003, Kool started Basic Pharma with Jacques Havermans and implemented the business concept of combining pharmaceutical licensing, manufacturing, supply and services under one roof. Kool's main responsibilities are Process & Product development, Business Development and Corporate Strategy.
Harry Relouw is responsible for general and financial management of Matisse. Relouw fills a similar position within Basic Pharma since early 2012 where he safeguards the alignment and execution of Basic Pharma's overall strategy.
He has more than twenty years of international experience in finance and operations, mainly in pharma and biotech. Before joining Matisse in 2014, , Relouw was Director Finance & Control at Prosensa Therapeutics, a Leiden based bio-pharmaceutical company till 2012. At Prosensa Therapeuticshe built the finance organisation of this fast growing company. Relouw was involved in private financing rounds, business planning and implementation of a collaboration agreement with GSK. Prior to Prosensa, Relouw worked in Senior Finance positions at Akzo Nobel, Ericsson, DSM, Rhein Biotech and the Korean based vaccine manufacturer GreenCross Vaccines, a company he helped to integrate in the Rhein Biotech Group. Relouw has a bachelor's degree in Finance & Control.
Dr Gerry Nicolaes
Gerry Nicolaes studied chemistry from 1987 till 1993 in Utrecht, the Netherlands, where he specialised in Biochemistry. In 1997 he received his PhD from the Faculty of Medicine of the Maastricht University , which was awarded a "cum laude" distinction.
After a short prolongation of the thesis work on the prothrombotic effects of oral contraceptives till early 1998, which received worldwide attention, he accepted a postdoctoral position at the Wallenberg Laboratory, University of Lund, Sweden. From late 2000 till present, he continued research on structure-function and drug discovery & design studies at the Biochemistry Department of CARIM after being granted a project grant and a successive VIDI grant to start an own research line, by the Netherlands Organisation for Scientific Research (NWO). Gerry published over 70 peer-reviewed scientific articles and supervised 8 doctorate candidates. Gerry will join Matisse Pharmaceuticals as a part-time CSO after Finance Round A.
Peter Ekhart, MSc MBA
Peter Ekhart has more than 23 years of experience in project management in multiple Life Science companies including Friesland Campina, TNO, Prosensa Therapeutics and ISA Therapeutics.
For Prosensa Therapeutics he managed two lead product development projects up to proof of concept resulting in the collaboration with GSK and recently a take over by Biomarin. At ISA, Ekhart realised the initiation of the first in man clinical study under GCP for the therapeutic vaccine against cervical cancer in 2013. In close collaboration with the UMCG and VU he organised and managed a clinical study for an oral hygiene product in Sjögren patients. For Aeon Astron he has managed the initiation of the BioCornea project resulting in a granted innovation credit loan of €3 M in 2012. Since 1990 Peter holds a master in (bio)chemistry, he completed a bioprocessing technology training at WUR in 1996 and he completed a MBA training in 2001.